Interviews

Carol R. Regueiro, MD, MSc, of Allegheny Health Network (AHN), explains how AHN's congestive heart failure bundle has enhanced collaboration between cardiology and primary care.

CMS is creating infrastructure to improve coverage of prescription digital therapeutics (PDTs), and new legislation would also drive uptake of PDTs.

Health care costs continue to rise despite lower demand, while younger generations increasingly face chronic health challenges.

Therapy selection for younger patients with myeloproliferative neoplasms (MPNs) may be different based on the desire for fertility preservation, but they are also at greater risk of their disease progressing, explained Ruben Mesa, MD, FACP, of Atrium Health.

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

UCB submitted a supplemental biologics license application for bimekuzimab (Bimzelyx) to the FDA in April for the drug’s approval in moderate to severe hidradenitis suppurativa (HS).

Carol R. Regueiro, MD, MSc, of Allegheny Health Network, described how AHN's Physician Partners of Western PA practice support model and shadow bundle distribution model enhanced collaboration between primary and specialty care to improve patient outcomes.

Leveraging Microsoft’s Azure OpenAI, Ontada streamlines oncology data analysis, reducing processing times by 85% to support clinical decisions and improve patient care for over 3000 oncologists across 30 states, according to Wanmei Ou, PhD, vice president of product, data analytics, and artificial intelligence (AI) at Ontada.

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients.

Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.

The theme of our recent Nashville Institute for Value-Based Medicine® event was ”Bringing the Future to the Present in Cancer Care.”

Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.

In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: minimal residual disease (MRD) status.

At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."

There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

Robert Lustig, MD, MSL, warns that sugary baby foods, rising birth weights, and ultraprocessed school meals are fueling long-term health risks in children.

Mabel Mardones, MD, board-certified medical oncologist and hematologist who specializes in breast cancer at Rocky Mountain Cancer Centers, emphasizes the importance in identifying patients with HR-positive, HER2-negative (HR+/HER2–) breast cancer with unmet treatment needs.

In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.

In our conversation with Jeff Giullian, MD, MBA, chief medical officer with DaVita Kidney Care, we dive into 4 important aspects of kidney care: prevention, social support, integrated care, and patient support.

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses advancements in breast cancer treatment, highlighting CDK4/6 inhibitors and antibody-drug conjugates as promising alternatives to traditional therapies.

While treatment options are evolving cancer care and extending lifespans, there is still a lack of biomarkers in certain cancers that can help direct treatment or provide early detection.

Glenn Balasky, executive director of Rocky Mountain Cancer Centers, emphasizes the need for government support to sustain telehealth and suggested a hybrid model combining centralized high-tech care with remote monitoring to address the challenges of providing innovative care in rural settings.

CMS made improvements for the Enhancing Oncology Model (EOM) over the Oncology Care Model (OCM), but there remains a delay in data and the challenge of high-cost, novel therapies, explained Stuart Staggs, vice president, Transformation and Shared Services, McKesson.

Viet Le, PA-C, Intermountain Health, gives insights into the benefits cardio-renal-metabolic care models provide for patients in need.

Navdeep Tangri, MD, PhD, FRCP, University of Manitoba, speaks to the value of population health strategies in clinical approaches to care delivery for patients with chronic kidney disease (CKD).

The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.

Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.

The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.

There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.